RhumbLine Advisers
VERV

RhumbLine Advisers’s Verve Therapeutics VERV Stock Holding History

RhumbLine Advisers’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-104,721
Closed -$1.18M – 4188
2025
Q2 		$1.18M Buy
104,721
+1,014
+1% +$5.78K ﹤0.01% 2162
2025
Q1 		$474K Sell
103,707
-7,496
-7% -$50.2K ﹤0.01% 2610
2024
Q4 		$627K Buy
111,203
+2,093
+2% +$11.8K ﹤0.01% 2527
2024
Q3 		$528K Sell
109,110
-3,336
-3% -$19.4K ﹤0.01% 2660
2024
Q2 		$549K Buy
112,446
+12,199
+12% +$76.7K ﹤0.01% 2610
2024
Q1 		$1.33M Buy
100,247
+19,047
+23% +$253K ﹤0.01% 2101
2023
Q4 		$1.13M Buy
81,200
+1,598
+2% +$19.8K ﹤0.01% 2190
2023
Q3 		$1.06M Buy
79,602
+219
+0.3% +$3.53K ﹤0.01% 2176
2023
Q2 		$1.49M Buy
79,383
+7,589
+11% +$126K ﹤0.01% 2074
2023
Q1 		$1.03M Buy
71,794
+3,861
+6% +$75.6K ﹤0.01% 2105
2022
Q4 		$1.31M Buy
67,933
+3,866
+6% +$102K ﹤0.01% 2004
2022
Q3 		$2.2M Buy
64,067
+13,304
+26% +$425K ﹤0.01% 1706
2022
Q2 		$776K Buy
50,763
+13,783
+37% +$213K ﹤0.01% 2264
2022
Q1 		$844K Buy
36,980
+19,156
+107% +$547K ﹤0.01% 2203
2021
Q4 		$657K Buy
17,824
+184
+1% +$7.73K ﹤0.01% 2395
2021
Q3 		$829K Buy
+17,640
New +$1.04M ﹤0.01% 2316

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

RhumbLine Advisers's VERV Position: Q3 2025 in Review

RhumbLine Advisers sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 104,721 shares — an estimated $1.18M sold.

RhumbLine Advisers first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $2.2M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • RhumbLine Advisers reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 104,721 Verve Therapeutics shares in Q3 2025, an estimated $1.18M.
  • RhumbLine Advisers first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • RhumbLine Advisers's Verve Therapeutics position peaked at $2.2M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.